Результаты поиска

Diagnosis, treatment, and follow-up of patients with hypophosphatasia.

INTRODUCTION: Hypophosphatasia is a rare inherited systemic metabolic disorder, with an estimated prevalence in the severe forms of the disease of 1/100.000-1/300.000, that affects the typical architecture of bone, leading to defective mineralization during growth and remodeling. It is characterized by loss-of-function variants in the ALPL gene, resulting in low activity of tissue-nonspecific alkaline phosphatase. In severe cases, it can be fatal. OBJECTIVE: To generate recommendations on the diagnosis, treatment, and follow-up of patients with hypophosphatasia based on available evidence. M

Совпадение в полном тексте источника
… Table 10 ERT Adverse events and management Adverse event Characteristics recommendations Allergic reactions Anaphylaxis: respiratory distress, nausea, angioedema, rash Hypersensitivity reaction: Fever, vomiting, skin rash, headache, irritability, chills, general or localized pruritus, oral hypoesthesia … Table 10 ERT Adverse events and management Source: adapted from [ 19 ] Adverse event | Characteristics | recommendations Allergic reactions | Anaphylaxis: respiratory distress, nausea, angioedema, rash Hypersensitivity reaction: Fever, vomiting, skin rash, headache, irritability, chills, general or localized …

Application Of Adoptive Immunotherapy In Ovarian Cancer.

Ovarian cancer (OC) has been the most fatal gynecological disease that threatens women's health. Surgery and platinum-based chemotherapy are the basic ovarian cancer treatments that can improve survival, but the five-year survival rate has not improved because of delayed diagnosis, drug resistance, and recurrence. Novel treatments are needed to improve the prognosis and survival rate of ovarian cancer patients. In recent years, adoptive cell therapy (ACT) has received increasing attention as an emerging therapeutic strategy in the treatment of solid tumors including OC. ACT has shown promising

Совпадение в полном тексте источника
… ORR and PFS after administration / / / NCT02541370 Unknown Ovarian Tumor, Colorectal Cancer, Acute Myeloid and Lymphoid Leukemias, etc Anti-CD133 CAR T cells Occurrence of study-related adverse events Anti-tumor responses to CART-133 cell infusions Mild chills, Fever, Fatigue, Vomiting and Muscle soreness … ORR and PFS after administration | / | / | / NCT02541370 | Unknown | Ovarian Tumor, Colorectal Cancer, Acute Myeloid and Lymphoid Leukemias, etc | Anti-CD133 CAR T cells | Occurrence of study-related adverse events | Anti-tumor responses to CART-133 cell infusions | Mild chills, Fever, Fatigue, Vomiting …

Teclistamab: First Approval.

Teclistamab (TECVAYLI®), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma. Teclistamab was recently granted conditional approval in the EU for the treatment of adult patients with relapsed and refractory multiple myeloma who have received three or more prior therapies (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody) and have demonstrated disease progression on the last therapy. Teclistamab was subsequently approve

Совпадение в полном тексте источника
… Of the patients who developed CRS, the most common (> 10% of patients) signs and symptoms were fever (72%), hypoxia (13%), chills (12%) and hypotension (12%). These occurred mostly during the first three doses of teclistamab. Only 0.6% of CRS events were grade 3. …

Unexpected massive bleeding caused by extensive maxillary osteonecrosis in a breast cancer patient: a case report.

Diphosphonate application is routinely recommended to treat bone metastasis (BM) in cancer patients. However, the severe side effects of diphosphonate, especially after long-term use, are often overlooked by clinicians. In this article, we describe a case in which a heavily-treated breast cancer patient, suffered from massive bleeding as a result of maxillary osteonecrosis by zoledronic acid (ZA) and apatinib. In October 2018, a 48-year-old Chinese female with breast cancer presented at our department with brain metastases. The patient had experienced progression multiple times and had receive

Совпадение в полном тексте источника
… The patient had no obvious symptoms, such as a high fever or chills, and the results of the laboratory examination excluded suppurative osteomyelitis. Radiation osteomyelitis was also excluded, as the patient had no history of radiotherapy in the maxillofacial region. …

Профилирование основанных на крови нейронных биомаркеров и цитокинов в экспериментальной аутоиммунной энцефаломиелитной модели множественного склероза с использованием технологии одномолекулярной арреи.

Экспериментальный аутоиммунный энцефаломиелит (EAE) — предклиническая животная модель, широко используемая для изучения множественного склероза (MS). Кровавые аналиты, включая цитокины и нейронные биомаркеры, являются предвестниками нейродегенерации, активности заболеваний и инвалидности у пациентов с MS. Однако недооцененные спутанные факторы приводят к вариациям в отчетах об ЭССХ между животными штаммами/исследованиями, ограничивая полезность этих биомаркеров для прогнозирования активности заболеваний. В ходе этого исследования мы изучили кровеносные аналитные профили, включая нейронные марк

Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review.

BackgroundPatients' self-report of their symptoms can provide important data for the evaluation of treatment benefit and tolerability of oncology drugs. Contemporary treatment approaches, including immunotherapy and molecular targeted therapies, have unique toxicities based on their novel mechanisms of action. This scoping review aimed to summarize evidence from existing reviews and clinical practice guidelines to examine the type and prevalence of toxicities including symptomatic adverse events (sympAEs) for adult cancer patients to inform clinical care and therapeutic trials.MethodsA systema

Совпадение в полном тексте источника
… VACCINES | Lalani (2017) | Review of trials data 1 phase 2 trial 1 phase 3 trial | Solid tumors (prostate, RCC, urothelial) | PSA (poxviral vaccine) Combination therapy (MVA-5T4 + IFN + IL-2, sunitinib) | GI: nausea Skin: erythema and itching Neuro: dizziness Pain: pain Sleep/Wake: fatigue Misc: fever, chills … There were no specific prevalence data provided in this review article for sympAEs, but they reported that cancer vaccines can cause symptoms such as nausea, skin erythema and pruritus, dizziness, pain, fatigue, chills, and fever. …

Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.

Nephrotic syndrome (NS) is a complex kidney disorder characterized by profound proteinuria, hypoalbuminemia, hyperlipidemia, and edema, significantly impacting patients' quality of life. While corticosteroids and calcineurin inhibitors (CNIs) have traditionally been the primary treatments, B cell-targeted therapies, especially the anti-CD20 monoclonal antibody rituximab, have transformed the management of steroid-dependent and multidrug-resistant NS (MRNS). Rituximab has demonstrated efficacy in reducing relapse rates and steroid dependence by depleting CD20+ B cells, which play a pivotal role

Совпадение в полном тексте источника
… Mild symptoms encompass fever, chills, rash, and headache, whereas severe instances may pose a threat to life [ 49 ]. All of these factors have spurred the investigation into innovative anti-CD20 molecules [ 4 , 42 ]. … The principal adverse effects linked to CD38 monoclonal antibodies include IRR (such as pyrexia, chills, and dyspnea), hematologic toxicities (including neutropenia, anemia, and hypogammaglobulinemia), and an elevated risk of infections. …

Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data.

Bispecific antibodies (bsAbs) are an emerging therapy in the treatment of large B-cell lymphomas (LBCLs). There is a gap in the research on the safety and efficacy of bsAbs in adults with LBCL, with current research focusing on the wider non-Hodgkin's lymphoma population. To address this research gap, we conducted a systematic review aiming to evaluate the safety and efficacy outcomes of bsAbs in adults with LBCL. A systematized search was conducted in PubMed, EMBASE, and CENTRAL on 10 April 2024. Interventional clinical trials were eligible for inclusion. Observational studies, reviews, and m

Совпадение в полном тексте источника
… Bannerji et al., investigating single-agent odronextamab, reported high rates of any grade chills (47%) and hypophosphatemia (29% any grade, 19% grade ≥3) [ 32 ]. … infection | 21.7 | C-reactive protein increased | 13 Pneumonia | 21.7 | Encephalopathy | 8.7 Diarrhea | 21.7 | Aphasia | 8.7 | | Hyperglycemia | 8.7 AZD0486 [ 30 ] | N/A | N/A | NR | NR TG-1801 [ 31 , 51 ] | Headache | 25 | Fall | 6 Abdominal pain | 25 | | COVID-19 | 25 | | Odronextamab [ 32 ] | Chills …

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.

The therapeutic options available for patients with multiple myeloma have greatly expanded over the past decade and incorporating these novel agents into routine clinical practice has significantly improved outcomes. The next generation of therapeutics is available for relapsed and refractory patients either as standard of care or in clinical trial, and these drugs represent a generational paradigm shift. Patients now have access to a multitude of novel immunotherapeutics, including monoclonal antibodies, an antibody-drug conjugate, chimeric antigen receptor T-cells (CAR-T), and bispecific T-c

Совпадение в полном тексте источника
… Associated symptoms are generally low grade and include chills, fever, nausea, nasal congestion, cough, and dyspnea. … Data from the ELOQUENT-2 and 3 trials demonstrated a 5–11% rate of all-grade IRR, events were all grade 1 or 2 except for five patients that had a grade 3 event on ELOQUENT-2. 16 , 39 Similar to daratumumab and isatuximab, the majority of these events were associated with fever, chills, cough, congestion …

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.

Subcutaneous delivery of biotherapeutics has become a valuable alternative to intravenous administration across many disease areas. Although the pharmacokinetic profiles of subcutaneous and intravenous formulations differ, subcutaneous administration has proven effective, safe, well-tolerated, generally preferred by patients and healthcare providers and to result in reduced drug delivery-related healthcare costs and resource use. The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from both health-economic and scientific perspectives. The article c

Совпадение в полном тексте источника
… These reaction symptoms can be characterized by flushing, rash, fever, rigors, chills, dyspnea, mild, and/or severe hypotension with(out) bronchospasms, cardiac dysfunction, and/or anaphylaxis. … IRRs were reported in 9 of 41 patients (22%) and were mostly grade 1/2 in severity; these included chills, fever, rigors, vomiting, itching, edema of the tongue, noncardiac chest pain, and wheezing. All IRRs developed during or within 6 h of the first subcutaneous infusion. …

Abstracts From JADPRO Live at APSHO 2017.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Infusion-related reactions (IRRs) include cough, dyspnea, bronchospasm, and chills. Between 45% and 71% of patients experienced an IRR on study, mainly with the first treatment. … This single patient reported gastrointestinal symptoms and chills during the first infusion and was able to safely continue treatment. …

Атипичные презентации Acolovir-Resistant Herpes Simplex Virus в иммунокомпромиссированных пациентах: Серия дел.

Инфекции, связанные с вирусом герпеса (HSV), у иммунокомпромиссированных пациентов могут иметь атипичные представления - от грануломатных до линейных эрозийных повреждений - и превращаться в рефракторную и стандартную терапию. Мы сообщаем three :: случаи некротизации категорической инфекции HSV у иммунокомпромиссированных пациентов с гематологическими малигнациями или предшествующими химиотерапиями, все из которых имеют нетипичные и рефракторные проявления заболевания. One дело касалось 53-year-old :: пациентка с реанимацией/рефрактом острой миэлоидной лейкемией (АМЛ), разработавшая некротизир

Совпадение в полном тексте источника
… She endorsed poor appetite, but denied experiencing fever, chills, or night sweats. On examination, there was a cluster of locally scattered, ulcerative, bleeding lesions over the coccyx and upper buttock region (Figure 8 ). …

Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma.

BackgroundWith the increasing use of daratumumab (DARA)-containing regimens for multiple myeloma (MM) patients in China, the standard infusion time of DARA is long, with the potential for infusion-related reactions (IRRs) and increased hospitalization and use of resources. Shortening the duration of DARA infusion helps to optimize the hospital stay and enhance the patient treatment experience. The current, commonly used 90-min rapid DARA infusion regimen may not be applicable to Chinese MM patients, and therefore, we explored a new 110-min rapid DARA infusion regimen aimed at reducing the trea

Совпадение в полном тексте источника
… Like for other monoclonal antibodies, infusion‐related adverse reactions (IRRs), including upper respiratory symptoms (cough, throat irritation, nasal congestion, wheezing, or shortness of breath), chills, rash, and gastrointestinal symptoms, are the most common adverse events (AEs) in patients treated …

Emergency Combination of Four Drugs for Bloodstream Infection Caused by Carbapenem-Resistant Enterobacteriaceae in Severe Agranulocytosis Patients with Hematologic Malignancies after Hematopoietic Stem Cell Transplantation.

Bloodstream infection (BSI) caused by multidrug-resistant (MDR) bacteria or extensively drug-resistant (XDR) bacteria is a global threat. However, an effective treatment regimen is still controversial and inadequate due to the rapid deterioration caused by the bacteria. In immunocompromised and neutropenic patients, MDR-BSI is an emergency, which causes treatment-related mortality. In this study, four agranulocytosis patients with hematologic malignancies after HSCT receiving treatment for carbapenem-resistant Enterobacteriaceae- (CRE-) BSI were included. Conventional treatment using two to th

Совпадение в полном тексте источника
… At day +3 posttransplantation, due to recurrent fever accompanied with chills and an increase of inflammatory markers, including IL-6 and procalcitonin, levofloxacin, 0.5 g, qd, sulperazone, 3 g, q12h, and indometacin were used. …

Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), representing approximately 25% of diagnosed NHL. DLBCL is heterogeneous disease both clinically and genetically. The 3 most common chromosomal translocations in DLBCL involve the oncogenes BCL2, BCL6, and MYC. Double hit (DH) DLBCL is an aggressive form in which MYC rearrangement is associated with either BCL2 or BCL6 rearrangement. Patients typically present with a rapidly growing mass, often with B symptoms. Extranodal disease is often present. Though there is a paucity of prospective trials in this

Совпадение в полном тексте источника
… The patient denied trauma, skin discharge, weight loss, fever, and night chills but had mild fatigue. A magnetic resonance imaging scan of lumbar spine was ordered by her primary doctor, which showed a diffuse abnormal signal over an area of about 11 cm × 8 cm. …

Concomitant plasma cell myeloma and chronic myelomonocytic leukemia in elderly: diagnostic complexity, therapeutic challenges - case report and literature review.

INTRODUCTION AND IMPORTANCE: Chronic Myelomonocytic Leukemia (CMML) is a rare clonal hematopoietic disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms. Its diagnosis becomes more challenging when coexisting with other hematologic malignancies. We report a rare dual pathology of CMML and plasma cell myeloma in an elderly female, highlighting the complexity of diagnosis and management. CASE PRESENTATION: An 82-year-old female, previously treated for cervical cancer, presented with bilateral buttock pain, gait disturbance, and weakness. Laboratory fin

Совпадение в полном тексте источника
… She denied weight loss, fever, chills, night sweats, numbness, tingling, weakness, dizziness, falls, trauma, or strenuous activity. She also denied smoking, alcohol, or illicit drug use, and her family history was noncontributory. …

C-Reactive Protein Monitoring and Clinical Presentation of Fever as Predictive Factors of Prolonged Febrile Neutropenia and Blood Culture Positivity after Autologous Hematopoietic Stem Cell Transplantation-Single-Center Real-Life Experience.

BackgroundFebrile neutropenia (FN) is a medical emergency that requires urgent evaluation, timely administration of empiric broad-spectrum antibiotics and careful monitoring in order to optimize the patient's outcome, especially in the setting of both allogeneic and autologous hematopoietic stem cell transplant (ASCT).MethodsIn this real-life retrospective study, a total of 49 consecutive episodes of FN were evaluated in 40 adult patients affected by either multiple myeloma (thirty-eight) or lymphoma (eleven), following ASCT, with nine patients having fever in both of the tandem transplantatio

Совпадение в полном тексте источника
… Characteristics of Febrile Neutropenia and Antimicrobial Treatment Febrile neutropenia occurred at a median of 7 days from PBSC reinfusion (range 2–11 days), associated with chills in all patients. Twelve patients suffered early fever onset within the first 5 days from ASCT. …

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

Ixazomib is the first oral proteasome inhibitor to be investigated in the clinic. This clinical study assessed whether the pharmacokinetics of ixazomib would be altered if administered after a high-calorie, high-fat meal. In a 2-period, 2-sequence, crossover study design, adult patients with advanced solid tumors or lymphoma received a 4-mg oral dose of ixazomib as immediate-release capsules on day 1 without food (fasted, administered following an overnight fast) or with food (fed, following consumption of a high-calorie, high-fat meal), followed by another dose on day 15 in the alternate food

Совпадение в полном тексте источника
… Any‐Grade Drug‐Related AE, n (%) | Safety Population (N = 24) Vomiting | 14 (58) Nausea | 12 (50) Fatigue | 6 (25) Rash a | 5 (21) Anemia | 4 (17) Weight loss | 4 (17) Decreased appetite | 3 (13) Diarrhea | 3 (13) Asthenia | 2 (8) Chills | 2 (8) Constipation | 2 (8) Thrombocytopenia | 2 (8) | Grade …

Резюме докладов 38th - ежегодное собрание общества общей внутренней медицины.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.

The therapeutic outcomes of clinical trials for incorporating anti-CD38 monoclonal antibodies (including isatuximab and daratumumab) into the bortezomib/lenalidomide/dexamethasone (VRd) triplet therapy backbone as the first-line treatment for newly diagnosed multiple myeloma (NDMM) have demonstrated significant improved efficacies. From a safety perspective, the addition of anti-CD38 monoclonal antibodies into the triplet therapies did not raise additional safety concerns. Based on the promising results, the National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 had updated the

Совпадение в полном тексте источника
… These reactions are typically mild and occur during the first infusion, presenting as symptoms such as fever, chills, and respiratory distress and are generally manageable with pre-infusion medications. … Early interventions for infections Management Strategies | Approach Prompt Assessment | • Patients undergoing quadruplet therapy should be educated to promptly report any signs of infection, such as fever, chills, or respiratory symptoms. • Clinicians should maintain a low threshold for initiating further …